IRON CHELATION AND VITAMIN-D3 IN COMBINATION WITH AZACITIDINE IMPROVES TREATMENT RESPONSE IN 19 HIGH RISK MYELODYSPLASTIC SYNDROMES AFTER AZACITIDINE FAILURE

被引：0
|
作者：
Brechemier, D. [1 ]
Comont, T. [1 ]
Bertoli, S. [2 ]
Dutertre, M. [1 ]
Recher, C. [2 ]
Adoue, D. [1 ]
Beyne-Rauzy, O. [1 ]
机构：
[1] Inst Univ Canc Toulouse Oncopole, Internal Med, Toulouse, France
[2] Inst Univ Canc Toulouse Oncopole, Hematol, Toulouse, France
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [41] THE OVERALL RESPONSE RATE OF AZACITIDINE IN PATIENTS WITH INTERMIDIATE-2 AND HIGH RISK MYELODYSPLASTIC SYNDROMES: A RETROSPECTIVE CHART REVIEW STUDY FROM GREECE
    Pappa, V
    Fragoulakis, V
    Maniadakis, N.
    Briasoulis, E.
    Tsionos, K.
    Kioumi, A.
    Vervesou, E.
    Symeonidis, A.
    VALUE IN HEALTH, 2014, 17 (03) : A223 - A224
  • [42] Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report
    Loukidis, Konstantinos
    Tschopp, Marcel
    LEUKEMIA RESEARCH REPORTS, 2024, 21
  • [43] Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
    Rautenberg, Christina
    Bergmann, Anika
    Germing, Ulrich
    Fischermanns, Caroline
    Pechtel, Sabrina
    Kaivers, Jennifer
    Jager, Paul
    Schuler, Esther
    Haas, Rainer
    Kobbe, Guido
    Schroeder, Thomas
    CANCERS, 2020, 12 (08) : 1 - 15
  • [44] Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
    Sebert, Marie
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Prebet, Thomas
    Cluzeau, Thomas
    Santini, Valeria
    Gyan, Emmanuel
    Sanna, Alessandro
    Ali, Najla Hai
    Hobson, Sean
    Eclache, Virginie
    List, Alan
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2017, 63 : 72 - 77
  • [45] A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece
    Vasiliki Pappa
    Achilles Anagnostopoulos
    Eleni Bouronikou
    Evangelos Briasoulis
    Ioannis Kotsianidis
    Maria Pagoni
    Panagiotis Zikos
    Konstantinos Tsionos
    Nora Viniou
    John Meletis
    Helen Papadaki
    Anna Kioumi
    Athanasios Galanopoulos
    Elisavet-Christine Vervessou
    Elias Poulakidas
    Panagiotis Karmas
    Kiki Karvounis
    Argiris Symeonidis
    International Journal of Hematology, 2017, 105 : 184 - 195
  • [46] Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
    Wei, Andrew H.
    Garcia, Jacqueline S.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nowak, Daniel
    Peterlin, Pierre
    Jurcic, Joseph
    Jacoby, Meagan A.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Hoffman, David
    Hogdal, Leah
    Naqvi, Kiran
    Kye, Steve
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S343
  • [47] A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece
    Pappa, Vasiliki
    Anagnostopoulos, Achilles
    Bouronikou, Eleni
    Briasoulis, Evangelos
    Kotsianidis, Ioannis
    Pagoni, Maria
    Zikos, Panagiotis
    Tsionos, Konstantinos
    Viniou, Nora
    Meletis, John
    Papadaki, Helen
    Kioumi, Anna
    Galanopoulos, Athanasios
    Vervessou, Elisavet-Christine
    Poulakidas, Elias
    Karmas, Panagiotis
    Karvounis, Kiki
    Symeonidis, Argiris
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (02) : 184 - 195
  • [48] Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
    Harel, Stephanie
    Cherait, Amina
    Berthon, Celine
    Willekens, Christophe
    Park, Sophie
    Rigal, Marthe
    Brechignac, Sabine
    Thepot, Sylvain
    Quesnel, Bruno
    Gardin, Claude
    Ades, Lionel
    Fenaux, Pierre
    Braun, Thorsten
    LEUKEMIA RESEARCH, 2015, 39 (05) : 501 - 504
  • [49] Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine
    Zeidan, Amer M.
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    List, Alan
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 705 - 710
  • [50] Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
    Cabezon, M.
    Malinverni, R.
    Bargay, J.
    Xicoy, B.
    Marce, S.
    Garrido, A.
    Tormo, M.
    Arenillas, L.
    Coll, R.
    Borras, J.
    Jimenez, M. J.
    Hoyos, M.
    Valcarcel, D.
    Escoda, L.
    Vall-Llovera, F.
    Garcia, A.
    Font, L. L.
    Ramila, E.
    Buschbeck, M.
    Zamora, L.
    CLINICAL EPIGENETICS, 2021, 13 (01)
12345